Are Investors Undervaluing CONMED (CNMD) Right Now?

02.12.25 15:40 Uhr

Werte in diesem Artikel
Aktien

33,60 EUR -0,60 EUR -1,75%

Indizes

935,5 PKT -8,9 PKT -0,94%

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One company to watch right now is CONMED (CNMD). CNMD is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock is trading with a P/E ratio of 10.69, which compares to its industry's average of 18.29. Over the last 12 months, CNMD's Forward P/E has been as high as 16.97 and as low as 10.31, with a median of 13.21. We also note that CNMD holds a PEG ratio of 1.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. CNMD's PEG compares to its industry's average PEG of 1.85. CNMD's PEG has been as high as 1.92 and as low as 0.68, with a median of 1.32, all within the past year.Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. CNMD has a P/S ratio of 1.02. This compares to its industry's average P/S of 1.38.Finally, investors should note that CNMD has a P/CF ratio of 8.23. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. CNMD's current P/CF looks attractive when compared to its industry's average P/CF of 18.79. Within the past 12 months, CNMD's P/CF has been as high as 13.46 and as low as 7.55, with a median of 9.15.These figures are just a handful of the metrics value investors tend to look at, but they help show that CONMED is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, CNMD feels like a great value stock at the moment.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Conmed und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Conmed

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Conmed

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Conmed Corp.

Wer­bung

Analysen zu Conmed Corp.

DatumRatingAnalyst
16.04.2019Conmed BuyNeedham & Company, LLC
23.01.2019Conmed BuyNeedham & Company, LLC
16.10.2018Conmed Equal WeightBarclays Capital
07.08.2018Conmed BuyNeedham & Company, LLC
02.08.2018Conmed BuyNeedham & Company, LLC
DatumRatingAnalyst
16.04.2019Conmed BuyNeedham & Company, LLC
23.01.2019Conmed BuyNeedham & Company, LLC
07.08.2018Conmed BuyNeedham & Company, LLC
02.08.2018Conmed BuyNeedham & Company, LLC
26.04.2018Conmed BuyNeedham & Company, LLC
DatumRatingAnalyst
16.10.2018Conmed Equal WeightBarclays Capital
22.10.2015Conmed Market PerformNorthland Capital
22.07.2015Conmed Market PerformNorthland Capital
10.02.2006CONMED DowngradeNeedham & Co
12.10.2005Update Conmed Corp. : HoldKeyBanc Capital Markets / McDonald
DatumRatingAnalyst
26.04.2005Update Conmed Corp. : UnderweightKeyBanc Capital Markets / McDonald

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Conmed Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen